Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
Related Experiment Video
Updated: Dec 10, 2025

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
Published on: August 16, 2020
C Ryan Oliver1, Trisha M Westerhof1, Maria G Castro2
1Department of Internal Medicine, University of Michigan Ann Arbor; Rogel Cancer Center, University of Michigan Ann Arbor.
Abstract:
Brain metastases are the most lethal cancer lesions; 10-30% of all cancers metastasize to the brain, with a median survival of only ~5-20 months, depending on the cancer type. To reduce the brain metastatic tumor burden, gaps in basic and translational knowledge need to be addressed. Major challenges include a paucity of reproducible preclinical models and associated tools. Three-dimensional models of brain metastasis can yield the relevant molecular and phenotypic data used to address these needs when combined with dedicated analysis tools. Moreover, compared to murine models, organ-on-a-chip models of patient tumor cells traversing the blood brain barrier into the brain microenvironment generate results rapidly and are more interpretable with quantitative methods, thus amenable to high throughput testing. Here we describe and demonstrate the use of a novel 3D microfluidic blood brain niche (µmBBN) platform where multiple elements of the niche can be cultured for an extended period (several days), fluorescently imaged by confocal microscopy, and the images reconstructed using an innovative confocal tomography technique; all aimed to understand the development of micro-metastasis and changes to the tumor micro-environment (TME) in a repeatable and quantitative manner. We demonstrate how to fabricate, seed, image, and analyze the cancer cells and TME cellular and humoral components, using this platform. Moreover, we show how artificial intelligence (AI) is used to identify the intrinsic phenotypic differences of cancer cells that are capable of transit through a model µmBBN and to assign them an objective index of brain metastatic potential. The data sets generated by this method can be used to answer basic and translational questions about metastasis, the efficacy of therapeutic strategies, and the role of the TME in both.
Insights
Researchers developed a novel 3D microfluidic blood-brain niche (µmBBN) platform to study brain metastasis. This innovative model uses artificial intelligence to predict brain metastatic potential, advancing cancer research.
Area of Science:
- Oncology
- Biomedical Engineering
- Neuroscience
Background:
- Brain metastases are a lethal complication of cancer, significantly reducing patient survival.
- Current preclinical models lack reproducibility and tools for studying brain metastasis.
- Understanding the tumor microenvironment (TME) is crucial for developing effective therapies.
Purpose of the Study:
- To introduce and validate a novel 3D microfluidic blood-brain niche (µmBBN) platform for studying brain metastasis.
- To enable quantitative and repeatable analysis of cancer cell behavior and TME interactions.
- To utilize artificial intelligence (AI) for predicting brain metastatic potential.
Main Methods:
- Fabrication and seeding of a 3D microfluidic platform mimicking the blood-brain barrier.
- Long-term culture and confocal imaging of cancer cells and TME components.
- Image reconstruction using confocal tomography and AI-driven phenotypic analysis.
Main Results:
- The µmBBN platform allows for extended culture and detailed imaging of brain micro-metastasis.
- AI successfully identified phenotypic differences in cancer cells capable of crossing the blood-brain barrier.
- An objective index for brain metastatic potential was assigned to cancer cells.
Conclusions:
- The µmBBN platform offers a reproducible and quantitative model for brain metastasis research.
- This platform facilitates the study of metastasis, TME role, and therapeutic strategies.
- AI integration provides a powerful tool for assessing metastatic potential and guiding treatment development.

